The SMi Group is proud to present their 11th annual Clinical Trials in CNS conference that will discuss the latest developments in preclinical discovery, clinical trial design, clinical trial management and neurodegenerative treatments.  

With increasing average life expectancy, these wide range of disorders (from Alzheimer’s, to Parkinson’s, MS, dementia and depression), are becoming increasingly widespread in the population, creating an ever- greater need for new treatments and therapies.  

Key reasons to attend:

Learn of the latest drug developments combating the key diseases in CNS, from Alzheimer's and dementia, to depression and schizophrenia

Discuss the cutting issues of the industry, from the ethics of outsourcing, to proving efficacy

Explore the latest innovations in pre-clinical discovery, trial optimisation and biomarker identification

Discover new ways to manage and adapt a clinical trial to ensure its success and efficiency  Network with key members of the industry involved in every part of clinical trials: from bench to bedside    

PLUS TWO INTERACTIVE HALF-DAY PRE-CONFERENCE WORKSHOPS
Wednesday 7th November, Copthorne Tara Hotel, 2012  

A: Ensuring efficiency and communication in partnerships within CNS clinical trials Lori Wright, President & CEO, Thievon-Wright Consulting Group
Steve Satek, Senior Vice President, Thievon-Wright Consulting Group
 8.30 – 12.30pm  

B:  Ethical decision making in clinical drug development
Michael Emanuel, Managing Director, SintoPharm
 13.00 – 5.00pm